TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited has announced the receipt of a $1.43 million R&D Tax Incentive rebate for the 2025 financial year. This rebate will be used to further develop their new asset, HMBD-002, as the company prepares to resume clinical trials in 2026. This development is significant for Percheron as it strengthens their financial position and supports their ongoing efforts in advancing oncology and rare disease therapies, potentially enhancing their industry standing and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company that focuses on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, and has completed a phase I clinical trial showing it to be generally safe and well-tolerated.
Average Trading Volume: 3,569,710
Technical Sentiment Signal: Sell
Current Market Cap: A$11.42M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.